How serious is the average FDA recall? About one in eleven is the most serious tier

The FDA's recall enforcement reports are the public record of every drug and medical-device recall the agency has logged — the recalling firm, the product, the reason, the geographic spread, and, most consequentially, a classification that grades how dangerous the FDA judged the problem to be. A recall sounds uniformly alarming, but the classification is where the meaning lives: a Class I recall is the agency's way of saying a product could seriously injure or kill, while a Class III recall covers problems unlikely to harm anyone at all. This study reads all 56,777 recalls on file and asks the obvious question the headlines rarely answer: when the FDA pulls a drug or a device, how serious is it usually?

Most recalls are not the most serious — but one in eleven is

Grade the 56,777 recalls by the FDA's own three-tier scale and the shape is clear. 5,237 recalls — 9.2%, about one in eleven — are Class I, the tier the FDA reserves for a reasonable probability of serious adverse health consequences or death. The large majority, 48,820 recalls (86.0%), are Class II: a defect is documented, but the agency judged the chance of serious harm temporary, reversible, or remote. The remaining 2,720 (4.8%) are Class III — violations unlikely to cause any harm, like a minor labeling error.

That 9.2% is the number to hold onto. It means the typical FDA recall is a mid-severity correction, not a life-threatening hazard — but it also means that across the full file, more than five thousand recalls carry the agency's most serious label, each one a product the FDA judged capable of causing serious injury or death.

About one in eleven FDA drug and device recalls carries the agency's most serious label — Class I, the tier it reserves for products it judges could seriously injure or kill.

Devices, not drugs, drive the volume

The file is not split evenly between the two product families. Medical devices account for 39,095 recalls (68.9%); drugs account for 17,682 (31.1%) — devices are recalled more than two to one over drugs. Part of that gap is structural: a single device design flaw or software fix can cascade into a recall spanning many models, lots, and serial ranges, so device recalls accumulate faster than drug recalls of comparable scope.

Source: FDA recall enforcement reports, classification by product kind, via the per-class rollup in the reproducibility block.

The two families carry similar Class I rates — 9.8% for drugs, 9.0% for devices — so the most serious recalls are roughly as common, proportionally, on each side. The difference is at the bottom of the scale: 9.6% of drug recalls are lowest-risk Class III versus just 2.6% of device recalls, and device recalls pile up in the middle, with 88.4% rated Class II. A drug recall is more likely to sit at either extreme; a device recall almost always lands in the mid-severity band.

Companies pull their own products — the FDA rarely orders it

The other striking fact is who initiates the recall. 56,430 of the 56,777 recalls (99.4%) are recorded as voluntary, firm-initiated withdrawals. Only 302 (0.5%) are marked FDA-mandated. Read carelessly, that looks like an agency that never forces the issue; read correctly, it reflects how the law is written.

In practice a recall is a negotiated, manufacturer-led process: the firm identifies a problem, proposes a correction or removal, and the FDA reviews and assigns the classification. The voluntary label is the default channel, not evidence that a problem was minor.

Recall volume over time

Recalls run at a steady few thousand a year, with no runaway trend. The annual counts below cover the eleven full calendar years from 2015 through 2025; 99.2% of the entire file falls in 2012 or later, so the years before that are too sparse to chart.

Source: FDA recall enforcement reports, by recall-initiation year. 2026 is excluded as a partial year.

Annual volume drifts down from roughly 4,600 recalls in the mid-2010s to about 3,600 in recent years, with a dip during 2020–2021. The Class I count is far noisier — 175 in 2016, 652 in 2018, 670 in 2023 — but those swings should not be read as the products suddenly getting more or less dangerous. Class I designations often attach to a cluster of related recalls from a single event, and classification can lag the initiation date, so any one year's Class I tally is sensitive to a handful of large actions.

What gets a product recalled

The recorded reasons differ by product family in a way that matches how each is made and used. For drugs, the dominant themes are contamination and sterility, out-of-specification or potency problems, and manufacturing-process failures — the recurring failure modes of chemistry and aseptic production. For devices, the reasons spread more evenly across contamination and sterility, labeling and packaging errors, and outright device defects or malfunctions. The reason text is free-form and a single recall can touch more than one theme, so these are directional signals rather than mutually exclusive categories, but the pattern is consistent: drug recalls are dominated by what is inside the product, device recalls by how the product is labeled, packaged, and built.

What one record actually is

Each row in fda_enforcement_reports is one recall enforcement record: a recalling firm, a product description, a reason, an FDA classification, and the dates the recall was initiated and reported. Rolling those rows up by classification, product_kind, and voluntary_mandated gives the severity, product, and initiation figures in this study. Because the unit is the recall event, no count or share here names, ranks, or singles out an individual manufacturer — the file describes the population of recalls, not a leaderboard of firms.

Methodology

All figures are aggregations over the fda_enforcement_reports table, populated from the FDA's recall enforcement reports via openFDA (drug and device enforcement endpoints). The table holds 56,777 recalls across 4,204 distinct recalling firms. The universe is every row; there is no suppression or sampling. Severity figures group by the FDA classification field (Class I / Class II / Class III); the product split groups by product_kind (drug / device); the voluntary share counts voluntary_mandated values beginning "Voluntary" against the total. The annual section groups by the calendar year of recall_initiation_date and reports only full years (2015–2025). Methodology version: fda-recalls/v1. The exact SQL is in the reproducibility block below and on the FDA Enforcement Reports dataset page.

Limitations

• Classification is the FDA's risk judgment, not an outcome. A Class I label means the agency judged a reasonable probability of serious harm at the time of the action; it does not mean anyone was harmed, and Class II/III recalls are not evidence that a product was safe to keep using.
• Voluntary vs mandated reflects the law. The 99.4% voluntary share is shaped by the FDA's limited statutory authority to compel recalls, especially for drugs, and is not a measure of how cooperative or negligent any firm was.
• Counts are recall events, not products, lots, or patients. One recall can span many models, lots, or units, and one event can generate several recall records; the file does not measure how many devices or drug units actually reached patients.
• Reason categories overlap. The reason field is free text, matched here by keyword, so the reason themes are directional and a single recall can fall under more than one.
• Point-in-time snapshot. Figures reflect the 2026-06-14 openFDA snapshot. The file is updated continuously and recalls are reclassified and terminated over time, so the bands shift between snapshots; the single pre-2004 outlier record is retained but immaterial to every share.
• Drug and device only, aggregate-only. The dataset covers FDA drug and device recalls; food, cosmetics, and tobacco recalls are out of scope. No recalling firm is named, ranked, or surfaced.

Sources

• openFDA — Drug Enforcement (recall) API — the federal drug-recall endpoint behind the drug rows in this study.
• openFDA — Device Enforcement (recall) API — the federal device-recall endpoint behind the device rows.
• FDA — Recalls, Market Withdrawals & Safety Alerts — the agency's definitions of Class I, II, and III recalls and the voluntary/mandated process.

The companion dataset page for FDA Enforcement Reports lists the schema and refresh cadence. For the federal-oversight context around these products, see who pays U.S. doctors the most — device makers, not pharma on the manufacturer side, and the OIG exclusion list, explained on the provider-enforcement side.